These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8959089)

  • 1. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption.
    Pfeilschifter J; Ziegler R
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):477-81. PubMed ID: 8959089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking and risk of Graves' disease.
    Prummel MF; Wiersinga WM
    JAMA; 1993 Jan; 269(4):479-82. PubMed ID: 8419666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism.
    Holm IA; Manson JE; Michels KB; Alexander EK; Willett WC; Utiger RD
    Arch Intern Med; 2005 Jul; 165(14):1606-11. PubMed ID: 16043678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' ophthalmopathy and tobacco smoking.
    Tallstedt L; Lundell G; Taube A
    Acta Endocrinol (Copenh); 1993 Aug; 129(2):147-50. PubMed ID: 8103953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graves' disease, endocrine ophthalmopathy and smoking.
    Winsa B; Mandahl A; Karlsson FA
    Acta Endocrinol (Copenh); 1993 Feb; 128(2):156-60. PubMed ID: 8451910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin.
    Tellez M; Cooper J; Edmonds C
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):291-4. PubMed ID: 1563082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is incidence of diplopia after Fat Removal Orbital Decompression a predictive factor of choice of surgical technique for Graves' ophthalmopathy?].
    Adenis JP; Camezind P; Robert PY
    Bull Acad Natl Med; 2003; 187(9):1649-58; discussion 1659-60. PubMed ID: 15369235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More on smoking habits and Graves' ophthalmopathy.
    Bartalena L; Martino E; Marcocci C; Bogazzi F; Panicucci M; Velluzzi F; Loviselli A; Pinchera A
    J Endocrinol Invest; 1989 Nov; 12(10):733-7. PubMed ID: 2614012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Graves' disease and the course of ophthalmopathy.
    Sridama V; DeGroot LJ
    Am J Med; 1989 Jul; 87(1):70-3. PubMed ID: 2741983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proptosis is associated with thiol-disulfide in patients with Graves' ophthalmopathy.
    Acibucu F; Öztürk DD; Kizildag C; Aslan MZ; Gulumsek E; Sumbul MS; Neselioglu S; Erel O; Sen S; Bankir M; Sumbul HE
    Arch Endocrinol Metab; 2022 Apr; 66(2):191-197. PubMed ID: 35315985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical manifestations of thyroid ophthalmopathy].
    Fernández Hermida RV; Pinar S; Muruzábal N
    An Sist Sanit Navar; 2008; 31 Suppl 3():45-56. PubMed ID: 19169294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of Graves' ophthalmopathy in an incidence cohort.
    Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
    Am J Ophthalmol; 1996 Mar; 121(3):284-90. PubMed ID: 8597271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double vision is a major manifestation in moderate to severe graves' orbitopathy, but it correlates negatively with inflammatory signs and proptosis.
    Laurberg P; Berman DC; Pedersen IB; Andersen S; Carlé A
    J Clin Endocrinol Metab; 2015 May; 100(5):2098-105. PubMed ID: 25695893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of diplopia following endoscopic orbital decompression: the orbital sling technique.
    Metson R; Samaha M
    Laryngoscope; 2002 Oct; 112(10):1753-7. PubMed ID: 12368609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.